Unicycive Therapeutics, Inc. (UNCY)
UNCY Stock Price Chart
Explore Unicycive Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze UNCY price movements and trends.
UNCY Company Profile
Discover essential business fundamentals and corporate details for Unicycive Therapeutics, Inc. (UNCY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Jul 2021
Employees
22.00
Website
https://www.unicycive.comCEO
Shalabh K. Gupta
Description
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
UNCY Financial Timeline
Browse a chronological timeline of Unicycive Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.47, while revenue estimate is $22.22m.
Earnings released on 12 May 2026
EPS came in at -$0.54 falling short of the estimated -$0.46 by -17.68%.
Earnings released on 30 Mar 2026
EPS came in at -$0.32 surpassing the estimated -$0.50 by +36.59%.
Earnings released on 12 Nov 2025
EPS came in at -$0.39 surpassing the estimated -$0.59 by +33.90%.
Earnings released on 14 Aug 2025
EPS came in at -$0.52 surpassing the estimated -$0.70 by +25.71%.
Stock split effective on 20 Jun 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Mar 2025
EPS came in at -$0.26 falling short of the estimated -$0.13 by -100.00%.
Earnings released on 27 Mar 2025
EPS came in at -$0.16 falling short of the estimated -$0.13 by -23.08%.
Earnings released on 12 Nov 2024
Earnings released on 14 Aug 2024
EPS came in at -$0.15 surpassing the estimated -$0.23 by +34.78%.
Earnings released on 13 May 2024
EPS came in at -$0.27 falling short of the estimated -$0.18 by -50.00%.
Earnings released on 28 Mar 2024
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%, while revenue for the quarter reached -$271.00k .
Earnings released on 14 Nov 2023
EPS came in at -$0.13 matching the estimated -$0.13.
Earnings released on 14 Aug 2023
EPS came in at -$0.29 surpassing the estimated -$0.39 by +25.64%.
Earnings released on 16 May 2023
EPS came in at -$0.29 surpassing the estimated -$0.36 by +19.44%, while revenue for the quarter reached $675.00k .
Earnings released on 31 Mar 2023
EPS came in at -$0.35 falling short of the estimated $0.24 by -245.83%.
Earnings released on 14 Nov 2022
EPS came in at -$0.37 falling short of the estimated -$0.35 by -5.71%, while revenue for the quarter reached $951.00k .
Earnings released on 15 Aug 2022
EPS came in at -$0.24 surpassing the estimated -$0.27 by +11.11%.
Earnings released on 12 May 2022
EPS came in at -$0.24 falling short of the estimated -$0.20 by -20.00%.
Earnings released on 31 Mar 2022
EPS came in at -$0.17 falling short of the estimated -$0.13 by -30.77%.
Earnings released on 11 Nov 2021
EPS came in at -$0.37 falling short of the estimated -$0.11 by -236.36%.
Earnings released on 16 Aug 2021
EPS came in at -$0.13 falling short of the estimated -$0.11 by -18.18%.
UNCY Stock Performance
Access detailed UNCY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
